Wegovy Titration: How the Dose Escalation Schedule Works

Why the titration schedule is built the way it is

The Wegovy dose schedule was not designed around convenience, it was built around tolerability data from the STEP clinical programme. In the STEP 1 trial, published in the New England Journal of Medicine, participants followed this exact stepwise escalation before reaching 2.4 mg, and the gastrointestinal side-effect profile (nausea, vomiting, diarrhoea, constipation) was most pronounced in the early weeks of each new dose, then settled. That is the biological pattern the schedule is designed around. Semaglutide slows gastric emptying and acts on appetite centres in the brain; both effects are felt more sharply when the dose changes. Each four-week hold gives receptors time to adjust before the next step up.

The licensed steps are fixed: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg and 1.7 mg in further four-week blocks, arriving at the 2.4 mg maintenance dose around week 17. Skipping a rung to get to a higher dose sooner is a common question, and the answer from prescribers is consistently the same. The evidence supports the gradual pathway; compressing it raises side-effect burden without meaningfully accelerating weight loss, because the therapeutic dose is 2.4 mg, not any of the steps below it. For a detailed breakdown of each rung and what to expect at each stage, including how each strength is supplied and measured, the Wegovy medication doses page covers the specifics, and the Wegovy titration schedule page sets the full progression out clearly.

What happens if titration needs to slow down or pause

Some people find a particular step more uncomfortable than expected. Nausea that disrupts daily life, persistent vomiting or significant diarrhoea are all reasons a prescriber may recommend staying at the current dose for an additional four weeks rather than advancing. This is not a failure, it is the schedule working as intended. The NHS medicines page for semaglutide confirms that side effects typically ease within a few days to two weeks of starting a new dose, but individual responses vary.

Pausing titration does not mean weight loss stops. Many people continue losing weight at a sub-maximal dose while their body settles. What matters is reaching 2.4 mg eventually at a pace that keeps you on treatment, rather than pushing too fast and stopping because side effects become unmanageable. Practical strategies your prescriber may discuss include timing your injection for an evening you can rest, eating smaller meals, avoiding fatty foods at the new dose level and staying well hydrated. These are conversations to have with your clinical team, not adjustments to make unilaterally.

For a longer trip or a period where supply might be interrupted, the question of whether you can skip a week of Wegovy for a holiday is answered separately, but the short version is that any break should involve your prescriber, not a solo decision.

Semaglutide titration and the 7.2 mg dose: what changed in 2026

For most patients, 2.4 mg is where the semaglutide journey ends. In January 2026 the MHRA approved a higher 7.2 mg weekly dose, initially supplied as three 2.4 mg pens administered each week. On 14 April 2026, the MHRA then approved a dedicated single-dose 7.2 mg pen for adults with a BMI of 30 or above. Trial data at this higher dose showed around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its highest licensed dose in head-to-head data. Titration still begins at 0.25 mg and moves through the same licensed steps; 7.2 mg is the new ceiling for those who tolerate 2.4 mg but a prescriber judges a further step is appropriate.

It is worth understanding that moving to 7.2 mg is a clinical decision, not an automatic progression. A prescriber reviews your response at 2.4 mg (weight trajectory, side-effect tolerance, any relevant health changes) before recommending the higher dose. If you are curious how semaglutide's escalation compares with other approaches, the semaglutide dose escalation page covers the broader picture, and the Wegovy doses page explains each strength in more detail. You can explore the full range of weight-loss treatment options we offer at the weight-loss treatments overview.

Titration, private prescribing and what to expect at each review

On the NHS, Wegovy is available only through specialist weight management services under NICE's appraisal criteria, waiting lists are long and access is tightly rationed. Private prescribing through a regulated online pharmacy removes the waiting list, but the clinical rigour around titration stays exactly the same. A prescriber reviews your case before every dose change, not just at the start.

At nume, that review happens the same day you request it, a named clinician reads your consultation, not software. Before a dose increase is approved, you provide evidence of your current weight and recent treatment history; our clinical team does not advance doses on request alone. Some patients ask about cost when a titration step means ordering a new pen mid-month, if that context is useful, the cost context for Wegovy in the UK page sets out what private pricing typically covers and what to look for. Timing your orders is practical: ordering by noon on a weekday means same-day dispatch and next-working-day delivery, worth bearing in mind around bank holidays or the end of the month when the urge to order at the last minute tends to strike.

If you want to understand the clinical process in more detail before committing to anything, our clinical team page explains who reviews your prescription. When you are ready, check your eligibility with a free consultation, there is no obligation and the assessment itself costs nothing.